Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721474 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00721474 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00721474, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.
Interventions
- DRUG Bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721474
The ClinicalTrials.gov registry entry for NCT00721474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bosutinib is the first listed.
NCT00721474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721474 about?
NCT00721474 is a clinical study titled "Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects". A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.
What is the current status of trial NCT00721474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00721474?
The interventions under investigation include: Bosutinib (DRUG).
Who is sponsoring clinical trial NCT00721474?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.